Here’s a bold statement: In a move that’s sure to spark both excitement and debate, Bristol Myers Squibb has just announced a dividend increase, marking its 17th consecutive year of doing so. But here’s where it gets controversial—while investors cheer, critics might question whether such consistent increases are sustainable in the long run. Let’s dive into the details.
On December 10, 2025, Bristol Myers Squibb (NYSE: BMY) revealed that its Board of Directors has approved a quarterly dividend of sixty-three cents ($0.63) per share on the company’s $0.10 par value common stock. This payout, scheduled for February 2, 2026, to shareholders on record as of January 2, 2026, represents a modest 1.6% increase from last year’s sixty-two cents ($0.62) per share. While the bump may seem small, it’s part of a larger trend—the company has now paid dividends for 94 consecutive years, a testament to its financial resilience.
And this is the part most people miss: At this rate, the annual dividend for fiscal year 2026 is projected to reach $2.52 per share, pending the Board’s regular quarterly review. This consistency raises an intriguing question: How does Bristol Myers Squibb balance innovation in life-saving medicines with rewarding shareholders year after year? Is this a sustainable model, or could it divert resources from critical research and development?
Adding to the announcement, the Board also declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on March 2, 2026, to shareholders of record as of February 3, 2026. This dual focus on both common and preferred shareholders underscores the company’s commitment to its investor base.
Bristol Myers Squibb, with its mission to ‘transform patients’ lives through science,’ continues to pursue groundbreaking research in serious diseases. But as the company celebrates this dividend milestone, it’s worth asking: Are dividend increases a sign of financial strength, or could they be a distraction from the core mission of medical innovation? Share your thoughts in the comments—we’d love to hear your perspective.
For more insights into Bristol Myers Squibb’s work, visit their website at BMS.com or follow them on social media platforms like LinkedIn, X, YouTube, Facebook, and Instagram. This announcement not only highlights the company’s financial strategy but also invites a broader conversation about the balance between shareholder returns and scientific advancement.
